Search
Transient receptor potential cation channel subfamily V member 4
go.drugbank.com/bio_entities/BE0009159TargetHumansPlays an obligatory role as a molecular component in the nonselective cation channel activation induced by 4-alpha-phorbol 12,13-didecanoate and hypotonic stimulation in synoviocytes and also regulates … Channel activity seems to be regulated by a calmodulin-dependent mechanism with a negative feedback mechanism (PubMed:12724311, PubMed:18826956).
Polypeptides: Transient receptor potential cation channel subfamily V member 4Synonyms: Osm-9-like TRP channel 4Transient receptor potential cation channel subfamily M member 4
go.drugbank.com/bio_entities/BE0009748TargetHumansPlays a role in keratinocyte differentiation (PubMed:30528822) … It thereby plays a central role in cadiomyocytes, neurons from entorhinal cortex, dorsal root and vomeronasal neurons, endocrine pancreas cells, kidney epithelial cells, cochlea hair cells etc.
Polypeptides: Transient receptor potential cation channel subfamily M member 4Synonyms: LTrpC-4, Melastatin-4CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4
go.drugbank.com/bio_entities/BE0014271TargetHumansCatalyzes the transfer of sialic acid (N-acetyl-neuraminic acid; Neu5Ac) from the nucleotide sugar donor CMP-Neu5Ac onto acceptor Galbeta-(1->3)-GalNAc- and Galbeta-(1->4)-GlcNAc-terminated glycoconjugates … Synthesizes ganglioside LM1 (IV3Neu5Ac-nLc4Cer), a major structural component of peripheral nerve myelin (PubMed:8611500)
Polypeptides: CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4Synonyms: ST-4, Alpha 2,3-ST 4Promazine
go.drugbank.com/drugs/DB00420ApprovedVet approvedWithdrawnA phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. … It is currently not approved for use in the United States.
Categories: Cytochrome P-450 Substrates, Adrenergic alpha-1 Receptor AntagonistsSynonyms: N,N-dimethyl-3-(10H-phenothiazin-10-yl)-propan-1-amine, N-(3-Dimethylaminopropyl)phenothiazineGalcanezumab
go.drugbank.com/drugs/DB14042ApprovedInvestigational[L42060] It is unknown if galcanezumab has an effect on pregnancy outcomes. A pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.[L42060] … Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin gene-related peptide (CGRP).
Products: EMGALİTY 120 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADET, EMGALİTY 120 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 3 ADETMethylene blue
go.drugbank.com/drugs/DB09241ApprovedInvestigationalIts use as an urinary tract antiseptic has also been investigated. … clinical trials to be an inhibitor of Tau protein aggregation.
Mixtures: UR N-C Urinary Antiseptic, Me NaPhos MB Hyo 1Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, MATE 1 InhibitorsMethylergometrine
go.drugbank.com/drugs/DB00353ApprovedInvestigationalA homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed)
Categories: Heterocyclic Compounds with 4 or More Rings, Cytochrome P-450 SubstratesSynonyms: 9,10-Didehydro-N-[1-(hydroxymethyl)-propyl]-D-lysergamide, D-lysergic acid 1-butanolamideFerric derisomaltose
go.drugbank.com/drugs/DB15617ApprovedInvestigational[A190528] Ferric derisomaltose is a form of iron used in the treatment of iron deficiency. This drug is a complex of iron (III) hydroxide and derisomaltose. … The latter is an iron carbohydrate oligosaccharide that works to release iron. Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020.
Products: MONOFER® SOLUTION FOR INJECTION OR INFUSION 100 MG/ML, Monofer 100 mg/ml solution for injection/infusion in vialsBurosumab
go.drugbank.com/drugs/DB14012ApprovedInvestigationalXLH is a serious disease which affects about 3,000 children and 12,000 adults in the United States. … This is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia (XLH), which is a rare, inherited form of rickets.
Products: CRYSVITA® SOLUCIÓN PARA INYECCIÓN 20 MG/ML, CRYSVITA® SOLUTION FOR INJECTION 10 MG/MLLetermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigational[L1021] It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors.[A31290] Letermovir has recieved both priority and orphan drug status from the FDA. … Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: PREVYMİS 240 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET, PREVYMİS 480 MG İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET